eligibility_summary
Adults (≥18) with IMWG-defined, measurable multiple myeloma, ECOG 0–2, ≥3 prior therapy lines (≥1 full cycle each unless PD), adequate labs, and life expectancy ≥3 months. Excludes prior GPRC5D/CD19 therapy, Waldenström, POEMS, or primary AL amyloidosis, active HBV/HCV/HIV, severe comorbidities or CAR‑T/DMSO allergy, pregnancy/breastfeeding or planning pregnancy, and concurrent trial enrollment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial tests two autologous CAR-T cell products, LCAR‑M61S and LCAR‑M61D (gene‑modified cellular immunotherapies). Patients undergo lymphodepletion with cyclophosphamide and fludarabine, then receive a single IV infusion. Mechanism: patient T cells are engineered to express a chimeric antigen receptor that recognizes myeloma‑associated surface antigens, antigen binding triggers CAR signaling, T‑cell activation, cytokine release, and cytotoxic killing of malignant plasma cells. Targets/cells: relapsed/refractory multiple myeloma plasma cells. The registry does not state the exact antigen(s), exclusion of prior GPRC5D/CD19‑directed therapy suggests these pathways/antigens may be targeted. Study assesses safety, tolerability, PK, and antitumor activity.